Looking to the horizon: The role of bilirubin in the development and prevention of age-related chronic diseases

Clinical Science

Volumn 129, Issue 1, 2015, Pages 1-25

  Wagner, Karl Heinz ^a   Wallner, Marlies ^a   Mölzer, Christine ^a   Gazzin, Silvia ^b   Bulmer, Andrew Cameron ^c   Tiribelli, Claudio ^b,d   Vitek, Libor ^e  

^a UNIVERSITY OF VIENNA   (Austria)

^b Italian Liver Foundation   (Italy)

^c GRIFFITH UNIVERSITY   (Australia)

^d UNIVERSITY OF TRIESTE   (Italy)

^e CHARLES UNIVERSITY   (Czech Republic)

Author keywords

All cause mortality; Bile pigment; Bilirubin; Biomarker; Cancer; Cardiovascular disease; Chronic disease; Gilbert's syndrome

Indexed keywords

BILE PIGMENT; BILIRUBIN; BIOLOGICAL MARKER;

AGING; BILIRUBIN METABOLISM; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; DEGENERATIVE DISEASE; DIABETES MELLITUS; HEART PROTECTION; HEMOSTASIS; HUMAN; INFLAMMATION; LIPID METABOLISM; METABOLIC SYNDROME X; MORTALITY; NEOPLASM; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE FUNCTION; VASCULAR DISEASE; BLOOD; NON INSULIN DEPENDENT DIABETES MELLITUS; PROGNOSIS; SURVIVAL RATE;

AGING; BILIRUBIN; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DIABETES MELLITUS, TYPE 2; HUMANS; NEOPLASMS; PROGNOSIS; SURVIVAL RATE;

EID: 84937511631     PISSN: 01435221     EISSN: 14708736     Source Type: Journal    
DOI: 10.1042/CS20140566     Document Type: Review

References (246)

1. Watchko, J.F. and Tiribelli, C. (2013) Bilirubin-induced neurologic damage-mechanisms and management approaches. N. Engl. J. Med. 369, 2021-2030.
2. Barateiro, A., Miron, V.E., Santos, S.D., Relvas, J.B., Fernandes, A., Ffrench-Constant, C. and Brites, D. (2013) Unconjugated bilirubin restricts oligodendrocyte differentiation and axonal myelination. Mol. Neurobiol. 47, 632-644.
3. Qaisiya, M., Coda Zabetta, C.D., Bellarosa, C. and Tiribelli, C. (2014) Bilirubin mediated oxidative stress involves antioxidant response activation via Nrf2 pathway. Cell. Signal. 26, 512-520.
4. Rao, P., Suzuki, R., Mizobuchi, S., Yamaguchi, T. and Sasaguri, S. (2006) Bilirubin exhibits a novel anti-cancer effect on human adenocarcinoma. Biochem. Biophys. Res. Commun. 342, 1279-1283.
5. Stocker, R., Yamamoto, Y., McDonagh, A.F., Glazer, A.N. and Ames, B.N. (1987) Bilirubin is an antioxidant of possible physiological importance. Science 235, 1043-1046.
6. Bulmer, A.C., Verkade, H.J. and Wagner, K.H. (2013) Bilirubin and beyond: a review of lipid status in Gilbert's syndrome and its relevance to cardiovascular disease protection. Prog. Lipid. Res. 52, 193-205.
7. Stocker, R. and Peterhans, E. (1989) Antioxidant properties of conjugated bilirubin and biliverdin: biologically relevant scavenging of hypochlorous acid. Free Radic. Res. Commun. 6, 57-66.
8. Bulmer, A.C., Ried, K., Coombes, J.S., Blanchfield, J.T., Toth, I. and Wagner, K.H. (2007) The anti-mutagenic and antioxidant effects of bile pigments in the Ames Salmonella test. Mutat. Res. 629, 122-132.
9. Molzer, C., Huber, H., Steyrer, A., Ziesel, G., Ertl, A., Plavotic, A., Wallner, M., Bulmer, A.C. and Wagner, K.H. (2012) In vitro antioxidant capacity and antigenotoxic properties of protoporphyrin and structurally related tetrapyrroles. Free Radic. Res. 46, 1369-1377.
10. Molzer, C., Huber, H., Diem, K., Wallner, M., Bulmer, A.C. and Wagner, K.H. (2013) Extracellular and intracellular anti-mutagenic effects of bile pigments in the Salmonella typhimurium reverse mutation assay. Toxicol. In Vitro 27, 433-437.
11. Molzer, C., Huber, H., Steyrer, A., Ziesel, G.V., Wallner, M., Hong, H.T., Blanchfield, J.T., Bulmer, A.C. and Wagner, K.H. (2013) Bilirubin and related tetrapyrroles inhibit food-borne mutagenesis: a mechanism for antigenotoxic action against a model epoxide. J. Nat. Prod. 76, 1958-1965.
12. De Flora, S., Rosenkranz, H.S. and Klopman, G. (1994) Structural basis of antimutagenicity of chemicals towards 4-nitroquinoline 1-oxide in Salmonella typhimurium. Mutagenesis 9, 39-45.
13. Camoirano, A., Balansky, R.M., Bennicelli, C., Izzotti, A., D'Agostini, F. and De Flora, S. (1994) Experimental databases on inhibition of the bacterial mutagenicity of 4-nitroquinoline 1-oxide and cigarette smoke. Mutat. Res. 317, 89-109.
14. Vitek, L., Jirsa, M., Brodanova, M., Kalab, M., Marecek, Z., Danzig, V., Novotny, L. and Kotal, P. (2002) Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis 160, 449-456.
15. Vitek, L. (2005) Impact of serum bilirubin on human diseases. Pediatrics 115, 1411-1412.
16. Vitek, L. and Schwertner, H.A. (2007) The heme catabolic pathway and its protective effects on oxidative stress-mediated diseases. Adv. Clin. Chem. 43, 1-57.
17. Vitek, L. and Ostrow, J.D. (2009) Bilirubin chemistry and metabolism; harmful and protective aspects. Curr. Pharm. Des. 15, 2869-2883.
18. Schwertner, H.A. and Vitek, L. (2008) Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk: possible protective effects and therapeutic applications of bilirubin. Atherosclerosis 198, 1-11.
19. Lin, J.P., Vitek, L. and Schwertner, H.A. (2010) Serum bilirubin and genes controlling bilirubin concentrations as biomarkers for cardiovascular disease. Clin. Chem. 56, 1535-1543.
20. Bulmer, A.C., Blanchfield, J.T., Toth, I., Fassett, R.G. and Coombes, J.S. (2008) Improved resistance to serum oxidation in Gilbert's syndrome: a mechanism for cardiovascular protection. Atherosclerosis 199, 390-396.
21. Horsfall, L.J., Rait, G., Walters, K., Swallow, D.M., Pereira, S.P., Nazareth, I. and Petersen, I. (2011) Serum bilirubin and risk of respiratory disease and death. JAMA 305, 691-697.
22. Vitek, L., Jirsa, Jr, M., Brodanová, M., Kalab, M., Marecek, Z., Danzig, V., Novotny, L. and Kotal, P. (2002) Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis 160, 449-456.
23. Vitek, L. and Schwertner, H.A. (2008) Protective effects of serum bilirubin on peripheral vascular disease. Ann. Hepatol. 7, 94-95.
24. Vitek, L., Zelenka, J., Zadinova, M. and Malina, J. (2005) The impact of intestinal microflora on serum bilirubin levels. J. Hepatol. 42, 238-243.
25. Temme, E.H., Zhang, J., Schouten, E.G. and Kesteloot, H. (2001) Serum bilirubin and 10-year mortality risk in a Belgian population. Cancer Causes Control 12, 887-894.
26. Zucker, S.D., Horn, P.S. and Sherman, K.E. (2004) Serum bilirubin levels in the U.S. population: gender effect and inverse correlation with colorectal cancer. Hepatology 40, 827-835.
27. Cox, A.J., Ng, M.C., Xu, J., Langefeld, C.D., Koch, K.L., Dawson, P.A., Carr, J.J., Freedman, B.I., Hsu, F.C. and Bowden, D.W. (2013) Association of SNPs in the UGT1A gene cluster with total bilirubin and mortality in the Diabetes Heart Study. Atherosclerosis 229, 155-160.
28. Vitek, L. (2012) The role of bilirubin in diabetes, metabolic syndrome, and cardiovascular diseases. Front. Pharmacol. 3, 55.
29. Wagner, K.H. and Brath, H. (2012) A global view on the development of non communicable diseases. Prev. Med. 54 (Suppl.), S38-S41.
30. Klatskin, G. (1961) Bile pigment metabolism. Annu. Rev. Med. 12, 211-250.
31. Schmid, R. and McDonagh, A.F. (1975) The enzymatic formation of bilirubin. Ann. N. Y. Acad. Sci. 244, 533-552.
32. Ryter, S.W., Alam, J. and Choi, A.M. (2006) Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol. Rev. 86, 583-650.
33. Rigato, I., Ostrow, J.D. and Tiribelli, C. (2005) Bilirubin and the risk of common non-hepatic diseases. Trends Mol. Med. 11, 277-283.
34. Brodersen, R. (1979) Bilirubin. Solubility and interaction with albumin and phospholipid. J. Biol. Chem. 254, 2364-2369.
35. Brodersen, R. (1980) Binding of bilirubin to albumin. CRC Crit. Rev. Clin. Lab. Sci. 11, 305-399.
36. Kamisako, T., Kobayashi, Y., Takeuchi, K., Ishihara, T., Higuchi, K., Tanaka, Y., Gabazza, E.C. and Adachi, Y. (2000) Recent advances in bilirubin metabolism research: the molecular mechanism of hepatocyte bilirubin transport and its clinical relevance. J. Gastroenterol. 35, 659-664.
37. Arias, I.M. (2012) Liver function from Y to Z. J. Clin. Invest. 122, 2763-2764.
38. Isselbacher, K.J. (1956) Enzymatic mechanisms of hormone metabolism. II. Mechanism of hormonal glucuronide formation. Recent Prog. Hormone Res. 12, 134-146.
39. Keitel, V., Nies, A.T., Brom, M., Hummel-Eisenbeiss, J., Spring, H. and Keppler, D. (2003) A common Dubin-Johnson syndrome mutation impairs protein maturation and transport activity of MRP2 (ABCC2). Am. J. Physiol. Gastrointest. Liver Physiol. 284, G165-G174.
40. Vitek, L. and Carey, M.C. (2003) Enterohepatic cycling of bilirubin as a cause of 'black' pigment gallstones in adult life. Eur. J. Clin. Invest. 33, 799-810.
41. Lester, R., Ostrow, J.D. and Schmid, R. (1961) Enterohepatic circulation of bilirubin. Nature 192, 372.
42. Gilbertsen, A.S., Bossenmaier, I. and Cardinal, R. (1962) Enterohepatic circulation of unconjugated bilirubin in man. Nature 196, 141-142.
43. Vitek, L., Majer, F., Muchova, L., Zelenka, J., Jiraskova, A., Branny, P., Malina, J. and Ubik, K. (2006) Identification of bilirubin reduction products formed by Clostridium perfringens isolated from human neonatal fecal flora. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 833, 149-157.
44. Vitek, L., Kotal, P., Jirsa, M., Malina, J., Cerna, M., Chmelar, D. and Fevery, J. (2000) Intestinal colonization leading to fecal urobilinoid excretion may play a role in the pathogenesis of neonatal jaundice. J. Pediatr. Gastroenterol. Nutr. 30, 294-298.
45. Stocker, R. (2004) Antioxidant activities of bile pigments. Antioxid. Redox Signal. 6, 841-849.
46. Berk, P.D., Rodkey, F.L., Blaschke, T.F., Collison, H.A. and Waggoner, J.G. (1974) Comparison of plasma bilirubin turnover and carbon monoxide production in man. J. Lab. Clin. Med. 83, 29-37.
47. Fulks, M., Stout, R.L. and Dolan, V.F. (2009) Mortality associated with bilirubin levels in insurance applicants. J. Insur. Med. 41, 49-53.
48. Ong, K.L., Allison, M.A., Cheung, B.M., Wu, B.J., Barter, P.J. and Rye, K.A. (2014) The relationship between total bilirubin levels and total mortality in older adults: the United States National Health and Nutrition Examination Survey (NHANES) 1999-2014. PLOS ONE 9, e94479.
49. Ajja, R., Lee, D.C., Sui, X., Church, T.S. and Steven, N.B. (2011) Usefulness of serum bilirubin and cardiorespiratory fitness as predictors of mortality in men. Am. J. Cardiol. 108, 1438-1442.
50. Horsfall, L.J., Nazareth, I. and Petersen, I. (2012) Cardiovascular events as a function of serum bilirubin levels in a large, statin-treated cohort. Circulation 126, 2556-2564.
51. Horsfall, L.J., Nazareth, I., Pereira, S.P. and Petersen, I. (2013) Gilbert's syndrome and the risk of death: a population-based cohort study. J. Gastroenterol. Hepatol. 28, 1643-1647.
52. Vasovic, O., Lalic, K., Trifunovic, D., Milic, N., Jevremovic, I., Popovic, L., Papalj, D., Milicevic-Kalasic, A., Sevo, G., Despotovic, N. et al. (2014) Prediction of cardiovascular mortality in functional disabled elderly-a possible new score. J. Med. Biochem. 33, 181-190.
53. Breimer, L.H., Wannamethee, G., Ebrahim, S. and Shaper, A.G. (1995) Serum bilirubin and risk of ischemic heart disease in middle-aged British men. Clin. Chem. 41, 1504-1508.
54. Novotny, L. and Vitek, L. (2003) Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp. Biol. Med. 228, 568-571.
55. Chen, Y.H., Hung, S.C. and Tarng, D.C. (2011) Serum bilirubin links UGT1A1*28 polymorphism and predicts long-term cardiovascular events and mortality in chronic hemodialysis patients. Clin. J. Am. Soc. Nephrol. 6, 567-574.
56. Zhu, C., Xiong, Z., Zheng, Z., Chen, Y., Chen, X. and Qian, X. (2012) Association of arterial stiffness with serum bilirubin levels in established coronary artery disease. Intern. Med. 51, 2083-2089.
57. Ohnaka, K., Kono, S., Inoguchi, T., Yin, G., Morita, M., Adachi, M., Kawate, H. and Takayanagi, R. (2010) Inverse associations of serum bilirubin with high sensitivity C-reactive protein, glycated hemoglobin, and prevalence of type 2 diabetes in middle-aged and elderly Japanese men and women. Diabetes Res. Clin. Pract. 88, 103-110.
58. Vitek, L. and Schwertner, H.A. (2007) The heme catabolic pathway and its protective effects on oxidative stress-mediated diseases. Adv. Clin. Chem. 43, 1-57.
59. Vitek, L. and Ostrow, J.D. (2009) Bilirubin chemistry and metabolism; harmful and protective aspects. Curr. Pharm. Des. 15, 2869-2883.
60. Bulmer, A.C., Verkade, H.J. and Wagner, K.H. (2013) Bilirubin and beyond: a review of lipid status in Gilbert's syndrome and its relevance to cardiovascular disease protection. Prog. Lipid Res. 52, 193-205.
61. Boon, A.C., Bulmer, A.C., Coombes, J.S. and Fassett, R.G. (2014) Circulating bilirubin and defense against kidney disease and cardiovascular mortality: mechanisms contributing to protection in clinical investigations. Am. J. Physiol. Renal Physiol. 307, F123-F136.
62. Wallner, M., Bulmer, A.C., Molzer, C., Mullner, E., Marculescu, R., Doberer, D., Wolzt, M., Wagner, O.F. and Wagner, K.H. (2013) Haem catabolism: a novel modulator of inflammation in Gilbert's syndrome. Eur. J. Clin. Invest. 43, 912-919.
63. Kunutsor, S.K., Bakker, S.J., Gansevoort, R.T., Chowdhury, R. and Dullaart, R.P. (2015) Circulating total bilirubin and risk of incident cardiovascular disease in the general population. Arterioscler. Thromb. Vasc. Biol. 35, 716-724.
64. Schwertner, H.A., Jackson, W.G. and Tolan, G. (1994) Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin. Chem. 40, 18-23.
65. Vitek, L., Jirsa, M., Brodanova, M., Kalab, M., Marecek, Z., Danzig, V., Novotny, L. and Kotal, P. (2002) Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis 160, 449-456.
66. Vitek, L., Novotny, L., Sperl, M., Holaj, R. and Spacil, J. (2006) The inverse association of elevated serum bilirubin levels with subclinical carotid atherosclerosis. Cerebrovasc. Dis. 21, 408-414.
67. Kang, S.J., Kim, D., Park, H.E., Chung, G.E., Choi, S.H., Choi, S.Y., Lee, W., Kim, J.S. and Cho, S.H. (2013) Elevated serum bilirubin levels are inversely associated with coronary artery atherosclerosis. Atherosclerosis 230, 242-248.
68. Tanaka, M., Fukui, M., Tomiyasu, K.I., Akabame, S., Nakano, K., Hasegawa, G., Oda, Y. and Nakamura, N. (2009) Low serum bilirubin concentration is associated with coronary artery calcification (CAC). Atherosclerosis 206, 287-291.
69. Mahabadi, A.A., Lehmann, N., Mohlenkamp, S., Kalsch, H., Bauer, M., Schulz, R., Moebus, S., Jockel, K.H., Erbel, R. and Heusch, G. (2014) Association of bilirubin with coronary artery calcification and cardiovascular events in the general population without known liver disease: the Heinz Nixdorf Recall study. Clin. Res. Cardiol. 103, 647-653.
70. Cure, E., Yuce, S., Cicek, Y. and Cure, M.C. (2013) The effect of Gilbert's syndrome on the dispersions of QT interval and P-wave: an observational study. Anadolu Kardiyol. Derg. 13, 559-565.
71. Qin, X.F. (2008) Bilirubin would be the indispensable component for some of the most important therapeutic effects of Calculus Bovis (Niuhuang). Chin. Med. J. (Engl.) 121, 480.
72. Ma, H., Zhou, J., Jiang, J., Duan, J., Xu, H., Tang, Y., Lv, G., Zhang, J., Zhan, Z. and Ding, A. (2012) The novel antidote Bezoar Bovis prevents the cardiotoxicity of toad (Bufo bufo gargarizans Canto) venom in mice. Exp. Toxicol. Pathol. 64, 417-423.
73. Ma, H., Zhang, J., Jiang, J., Zhou, J., Xu, H., Zhan, Z., Wu, Q. and Duan, J. (2012) Bilirubin attenuates bufadienolide-induced ventricular arrhythmias and cardiac dysfunction in guinea-pigs by reducing elevated intracellular Na+ levels. Cardiovasc. Toxicol. 12, 83-89.
74. Perlstein, T.S., Pande, R.L., Beckman, J.A. and Creager, M.A. (2008) Serum total bilirubin level and prevalent lower-extremity peripheral arterial disease: National Health and Nutrition Examination Survey (NHANES) 1999 to 2004. Arterioscler. Thromb. Vasc. Biol. 28, 166-172.
75. Perlstein, T.S., Pande, R.L., Creager, M.A., Weuve, J. and Beckman, J.A. (2008) Serum total bilirubin level, prevalent stroke, and stroke outcomes: NHANES 1999-2004. Am. J. Med. 121, 781-788.
76. Balta, S., Balta, I., Mikhailidis, D.P., Ozturk, C., Demirkol, S., Celik, T., Kilic, S., Demir, M. and Iyisoy, A. (2014) Bilirubin levels and their association with carotid intima media thickness and high-sensitivity C-reactive protein in patients with psoriasis vulgaris. Am. J. Clin. Dermatol. 15, 137-142.
77. Erdogan, D., Gullu, H., Yildirim, E., Tok, D., Kirbas, I., Ciftci, O., Baycan, S.T. and Muderrisoglu, H. (2006) Low serum bilirubin levels are independently and inversely related to impaired flow-mediated vasodilation and increased carotid intima-media thickness in both men and women. Atherosclerosis 184, 431-437.
78. Chen, X., Lou, G., Meng, Z. and Huang, W. (2011) TGR5: a novel target for weight maintenance and glucose metabolism. Exp. Diabetes Res. 2011, 853501.
79. Kim, K.M., Kim, B.T., Park, S.B., Cho, D.Y., Je, S.H. and Kim, K.N. (2012) Serum total bilirubin concentration is inversely correlated with Framingham risk score in Koreans. Arch. Med. Res. 43, 288-293.
80. Ben-Amotz, R., Bonagura, J., Velayutham, M., Hamlin, R., Burns, P. and Adin, C. (2014) Intraperitoneal bilirubin administration decreases infarct area in a rat coronary ischemia/reperfusion model. Front. Physiol. 5, 53.
81. Bakrania, B., Du Toit, E.F., Ashton, K.J., Kiessling, C.J., Wagner, K.H., Headrick, J.P. and Bulmer, A.C. (2014) Hyperbilirubinemia modulates myocardial function, aortic ejection and ischemic stress-resistance in the Gunn rat. Am. J. Physiol. Heart Circ. Physiol. 307, H1142-H1149.
82. Horsfall, L.J., Rait, G., Walters, K., Swallow, D.M., Pereira, S.P., Nazareth, I. and Petersen, I. (2011) Serum bilirubin and risk of respiratory disease and death. JAMA 305, 691-697.
83. Lenicek, M., Duricova, D., Hradsky, O., Dusatkova, P., Jiraskova, A., Lukas, M., Nachtigal, P. and Vitek, L. (2014) The relationship between serum bilirubin and Crohn's disease. Inflamm. Bowel Dis. 20, 481-487.
84. Vitek, L., Muchova, L., Jancova, E., Pesickova, S., Tegzova, D., Peterova, V., Pavelka, K. and Tesar, V. (2010) Association of systemic lupus erythematosus with low serum bilirubin levels. Scand. J. Rheumatol. 39, 480-484.
85. Fischman, D., Valluri, A., Gorrepati, V.S., Murphy, M.E., Peters, I. and Cheriyath, P. (2010) Bilirubin as a protective factor for rheumatoid arthritis: an NHANES study of 2003-2006 data. J. Clin. Med. Res. 2, 256-260.
86. Vitek, L., Novotna, M., Lenicek, M., Novotny, L., Eberova, J., Petrasek, J. and Jirsa, M. (2010) Serum bilirubin levels and UGT1A1 promoter variations in patients with schizophrenia. Psychiatry Res. 178, 449-450.
87. Peng, F., Deng, X., Yu, Y., Chen, X., Shen, L., Zhong, X., Qiu, W., Jiang, Y., Zhang, J. and Hu, X. (2011) Serum bilirubin concentrations and multiple sclerosis. J. Clin. Neurosci. 18, 1355-1359.
88. Bian, L.Q., Li, R.Z., Zhang, Z.Y., Jin, Y.J., Kang, H.W., Fang, Z.Z., Park, Y.S. and Choi, Y.H. (2013) Effects of total bilirubin on the prevalence of osteoporosis in postmenopausal women without potential liver disease. J. Bone Miner. Metab. 31, 637-643.
89. Breslin, E., Kaufmann, A. and Quenby, S. (2013) Bilirubin influences the clinical presentation of pre-eclampsia. Eur. J. Obstet. Gyn. Reprod. Biol. 170, 111-113.
90. Coumbe, A.G., Pritzker, M.R. and Duprez, D.A. (2014) Cardiovascular risk and psoriasis: beyond the traditional risk factors. Am. J. Med. 127, 12-18.
91. Scalzi, L.V., Ballou, S.P., Park, J.Y., Redline, S. and Kirchner, H.L. (2008) Cardiovascular disease risk awareness in systemic lupus erythematosus patients. Arthritis Rheum. 58, 1458-1464.
92. Kayahan, H., Sari, I., Cullu, N., Yuksel, F., Demir, S., Akarsu, M., Goktay, Y., Unsal, B. and Akpinar, H. (2012) Evaluation of early atherosclerosis in patients with inflammatory bowel disease. Dig. Dis. Sci. 57, 2137-2143.
93. Anagnostis, P., Karagiannis, A., Kakafika, A.I., Tziomalos, K., Athyros, V.G. and Mikhailidis, D.P. (2009) Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities? Osteoporos. Int. 20, 197-207.
94. Garcia-Gomez, C., Bianchi, M., de la Fuente, D., Badimon, L., Padro, T., Corbella, E. and Pinto, X. (2014) Inflammation, lipid metabolism and cardiovascular risk in rheumatoid arthritis: a qualitative relationship? World J. Orthop. 5, 304-311.
95. Christiansen, C.F., Christensen, S., Farkas, D.K., Miret, M., Sorensen, H.T. and Pedersen, L. (2010) Risk of arterial cardiovascular diseases in patients with multiple sclerosis: a population-based cohort study. Neuroepidemiology 35, 267-274.
96. McDonald, S.D., Ray, J., Teo, K., Jung, H., Salehian, O., Yusuf, S. and Lonn, E. (2013) Measures of cardiovascular risk and subclinical atherosclerosis in a cohort of women with a remote history of preeclampsia. Atherosclerosis 229, 234-239.
97. Unsal, C., Oran, M., Tureli, H.O., Alpsoy, S., Yesilyurt, S., Arslan, M., Topcu, B., Karakaya, O. and Kurt, E. (2013) Detection of subclinical atherosclerosis and diastolic dysfunction in patients with schizophrenia. Neuropsychiatr. Dis. Treat. 9, 1531-1537.
98. Ghoorah, K., De Soyza, A. and Kunadian, V. (2013) Increased cardiovascular risk in patients with chronic obstructive pulmonary disease and the potential mechanisms linking the two conditions: a review. Cardiol. Rev. 21, 196-202.
99. Stocker, R., Yamamoto, Y., McDonagh, A.F., Glazer, A.N. and Ames, B.N. (1987) Bilirubin is an antioxidant of possible physiological importance. Science 235, 1043-1046.
100. Wu, T.W., Fung, K.P., Wu, J., Yang, C.C. and Weisel, R.D. (1996) Antioxidation of human low density lipoprotein by unconjugated and conjugated bilirubins. Biochem. Pharmacol. 51, 859-862.
101. Wu, T.W., Fung, K.P. and Yang, C.C. (1994) Unconjugated bilirubin inhibits the oxidation of human low density lipoprotein better than Trolox. Life Sci. 54, P477-P481.
102. Vítek, L., Novotný, L., Žák, A., Staňková, B., Zima, T., Polito, A., Cesare, G., Zerbinati, C. and Iuliano, L. (2013) Relationship between serum bilirubin and uric acid to oxidative stress markers in Italian and Czech populations. J. Appl. Biomed. 11, 209-221.
103. Vitek, L., Kraslova, I., Muchova, L., Novotny, L. and Yamaguchi, T. (2007) Urinary excretion of oxidative metabolites of bilirubin in subjects with Gilbert syndrome. J. Gastroenterol. Hepatol. 22, 841-845.
104. Kalousova, M., Novotny, L., Zima, T., Braun, M. and Vitek, L. (2005) Decreased levels of advanced glycation end-products in patients with Gilbert syndrome. Cell. Mol. Biol. 51, 387-392.
105. Boon, A.C., Hawkins, C.L., Bisht, K., Coombes, J.S., Bakrania, B., Wagner, K.H. and Bulmer, A.C. (2012) Reduced circulating oxidized LDL is associated with hypocholesterolemia and enhanced thiol status in Gilbert syndrome. Free Radic. Biol. Med. 52, 2120-2127.
106. Datla, S.R., Dusting, G.J., Mori, T.A., Taylor, C.J., Croft, K.D. and Jiang, F. (2007) Induction of heme oxygenase-1 in vivo suppresses NADPH oxidase derived oxidative stress. Hypertension 50, 636-642.
107. Lanone, S., Bloc, S., Foresti, R., Almolki, A., Taille, C., Callebert, J., Conti, M., Goven, D., Aubier, M., Dureuil, B. et al. (2005) Bilirubin decreases nos2 expression via inhibition of NAD(P)H oxidase: implications for protection against endotoxic shock in rats. FASEB J. 19, 1890-1892.
108. Schwertner, H.A. and Fischer, Jr, J.R. (2000) Comparison of various lipid, lipoprotein, and bilirubin combinations as risk factors for predicting coronary artery disease. Atherosclerosis 150, 381-387.
109. Tapan, S., Karadurmus, N., Dogru, T., Ercin, C.N., Tasci, I., Bilgi, C., Kurt, I. and Erbil, M.K. (2011) Decreased small dense LDL levels in Gilbert's syndrome. Clin. Biochem. 44, 300-303.
110. Wallner, M., Marculescu, R., Doberer, D., Wolzt, M., Wagner, O., Vitek, L., Bulmer, A.C. and Wagner, K.H. (2013) Protection from age-related increase in lipid biomarkers and inflammation contributes to cardiovascular protection in Gilbert's syndrome. Clin. Sci. 125, 257-264.
111. Kotani, K., Tsuzaki, K. and Sakane, N. (2014) The relationship between gamma-glutamyltransferase (GGT), bilirubin (Bil) and small dense low-density lipoprotein (sdLDL) in asymptomatic subjects attending a clinic for screening dyslipidaemias. Ann. Acad. Med. Singap. 43, 216-219.
112. Ocadlik, I., Hlinstakova, S. and Oravec, S. (2011) Relationship between unconjugated hyperbilirubinemia and lipoprotein spectrum. Neuro Endocrinol. Lett. 32, 360-364.
113. Oda, E. (2014) A decrease in total bilirubin predicted hyper-LDL cholesterolemia in a health screening population. Atherosclerosis 235, 334-338.
114. Kamisako, T., Masuda, S. and Tanaka, Y. (2013) Relationship between serum bilirubin and remnant lipoprotein cholesterol level. Clin. Lab. 59, 435-438.
115. Kohli, P. and Cannon, C.P. (2012) Triglycerides: how much credit do they deserve? Med. Clin. North. Am. 96, 39-55.
116. Sharma, R.K., Singh, V.N. and Reddy, H.K. (2009) Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk. Vasc. Health Risk Manag. 5, 793-799.
117. Miller, M., Cannon, C.P., Murphy, S.A., Qin, J., Ray, K.K. and Braunwald, E.; PROVE IT-TIMI 22 investigators (2008) Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J. Am. Coll. Cardiol. 51, 724-730.
118. McNamara, J.R., Shah, P.K., Nakajima, K., Cupples, L.A., Wilson, P.W., Ordovas, J.M. and Schaefer, E.J. (2001) Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis 154, 229-236.
119. Andersson, C., Weeke, P., Fosbol, E.L., Brendorp, B., Kober, L., Coutinho, W., Sharma, A.M., Van Gaal, L., Finer, N., James, W.P. et al. (2009) Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. Metabolism 58, 1109-1115.
120. Belo, L., Nascimento, H., Kohlova, M., Bronze-da-Rocha, E., Fernandes, J., Costa, E., Catarino, C., Aires, L., Mansilha, H.F., Rocha-Pereira, P. et al. (2014) Body fat percentage is a major determinant of total bilirubin independently of UGT1A1*28 polymorphism in young obese. PLOS ONE 9, e98467.
121. Inoguchi, T., Sasaki, S., Kobayashi, K., Takayanagi, R. and Yamada, T. (2007) Relationship between Gilbert syndrome and prevalence of vascular complications in patients with diabetes. JAMA 298, 1398-1400.
122. Puri, K., Nobili, V., Melville, K., Corte, C.D., Sartorelli, M.R., Lopez, R., Feldstein, A.E. and Alkhouri, N. (2013) Serum bilirubin level is inversely associated with nonalcoholic steatohepatitis in children. J. Pediatr. Gastroenterol. Nutr. 57, 114-118.
123. Salomone, F., Li Volti, G., Rosso, C., Grosso, G. and Bugianesi, E. (2013) Unconjugated bilirubin, a potent endogenous antioxidant, is decreased in patients with non-alcoholic steatohepatitis and advanced fibrosis. J. Gastroenterol. Hepatol. 28, 1202-1208.
124. Kwak, M.S., Kim, D., Chung, G.E., Kang, S.J., Park, M.J., Kim, Y.J., Yoon, J.H. and Lee, H.S. (2012) Serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease. Clin. Mol. Hepatol. 18, 383-390.
125. Dong, H., Huang, H., Yun, X., Kim, D.S., Yue, Y., Wu, H., Sutter, A., Chavin, K.D., Otterbein, L.E., Adams, D.B. et al. (2014) Bilirubin increases insulin sensitivity in leptin-receptor deficient and diet-induced obese mice through suppression of ER stress and chronic inflammation. Endocrinology 155, 818-828.
126. Guzek, M., Jakubowski, Z., Bandosz, P., Wyrzykowski, B., Smoczynski, M., Jabloiska, A. and Zdrojewski, T. (2012) Inverse association of serum bilirubin with metabolic syndrome and insulin resistance in Polish population. Przeg. Epidemiol. 66, 495-501.
127. Dullaart, R.P., Boersema, J., Lefrandt, J.D., Wolffenbuttel, B.H. and Bakker, S.J. (2014) The inverse association of incident cardiovascular disease with plasma bilirubin is unaffected by adiponectin. Atherosclerosis 235, 380-383.
128. Kubota, N., Terauchi, Y., Yamauchi, T., Kubota, T., Moroi, M., Matsui, J., Eto, K., Yamashita, T., Kamon, J., Satoh, H. et al. (2002) Disruption of adiponectin causes insulin resistance and neointimal formation. J. Biol. Chem. 277, 25863-25866.
129. Cure, E., Cicek, Y., Cumhur Cure, M., Yuce, S., Kirbas, A. and Yilmaz, A. (2013) The evaluation of relationship between adiponectin levels and epicardial adipose tissue thickness with low cardiac risk in Gilbert's syndrome: an observational study. Anadolu Kardiyol. Derg. 13, 791-796.
130. Lee, M.J., Jung, C.H., Kang, Y.M., Hwang, J.Y., Jang, J.E., Leem, J., Park, J.Y., Kim, H.K. and Lee, W.J. (2014) Serum bilirubin as a predictor of incident metabolic syndrome: a 4-year retrospective longitudinal study of 6205 initially healthy Korean men. Diabetes Metab. 40, 305-309.
131. Jung, C.H., Lee, M.J., Kang, Y.M., Hwang, J.Y., Jang, J.E., Leem, J., Park, J.Y., Kim, H.K. and Lee, W.J. (2014) Higher serum bilirubin level as a protective factor for the development of diabetes in healthy Korean men: a 4 year retrospective longitudinal study. Metabolism 63, 87-93.
132. Kwon, K.-M., Kam, J.-H., Kim, M.-Y., Kim, M.-Y., Chung, C.H., Kim, J.-K., Linton, J.A., Eom, A., Koh, S.-B. and Kang, H.-T. (2011) Inverse association between total bilirubin and metabolic syndrome in rural Korean women. J. Womens Health 20, 963-969.
133. Chan, K.H., O'Connell, R.L., Sullivan, D.R., Hoffmann, L.S., Rajamani, K., Whiting, M., Donoghoe, M.W., Vanhala, M., Hamer, A., Yu, B. et al. (2013) Plasma total bilirubin levels predict amputation events in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia 56, 724-736.
134. Jiraskova, A., Jovanovska, J., Skrha, J. and Vitek, L. (2011) Association of low bilirubin levels and promoter variations in UGT1A1 gene with diabetes mellitus type 2. Hepatol. Int. 5, 37.
135. Bossard, M., Aeschbacher, S., Schoen, T., Hochgruber, T., von Rotz, M., Blum, J., Risch, M., Risch, L. and Conen, D. (2014) Serum bilirubin levels and risk of prediabetes in young and healthy adults. Int. J. Cardiol. 171, e24-25.
136. Mishra, M. and Ndisang, J.F. (2014) A critical and comprehensive insight on heme oxygenase and related products including carbon monoxide, bilirubin, biliverdin and ferritin in type-1 and type-2 diabetes. Curr. Pharm. Des. 20, 1370-1391.
137. Deetman, P.E., Bakker, S.J., Kwakernaak, A.J., Navis, G. and Dullaart, R.P. (2014) The relationship of the anti-oxidant bilirubin with free thyroxine is modified by insulin resistance in euthyroid subjects. PLOS ONE 9, e90886.
138. Libby, P., Ridker, P.M. and Hansson, G.K. (2009) Inflammation in atherosclerosis: from pathophysiology to practice. J. Am. Coll. Cardiol. 54, 2129-2138.
139. Najib-Farah, M.D. (1937) Defensive role of bilirubinemia in pneumococcal infection. Lancet 229, 505-506.
140. Basiglio, C.L., Arriaga, S.M., Pelusa, F., Almara, A.M., Kapitulnik, J. and Mottino, A.D. (2010) Complement activation and disease: protective effects of hyperbilirubinaemia. Clin. Sci. 118, 99-113.
141. Haga, Y., Tempero, M.A. and Zetterman, R.K. (1996) Unconjugated bilirubin inhibits in vitro cytotoxic T lymphocyte activity of human lymphocytes. Biochim. Biophys. Acta 1317, 65-70.
142. Rocuts, F., Zhang, X., Yan, J., Yue, Y., Thomas, M., Bach, F.H., Czismadia, E. and Wang, H. (2010) Bilirubin promotes de novo generation of T regulatory cells. Cell Transplant 19, 443-451.
143. Eklund, C.M. (2009) Proinflammatory cytokines in CRP baseline regulation. Adv. Clin. Chem. 48, 111-136.
144. Hwang, H.J., Lee, S.W. and Kim, S.H. (2011) Relationship between bilirubin and C-reactive protein. Clin. Chem. Lab. Med. 49, 1823-1828.
145. Vitek, L., Malikova, I., Kvasnicka, J., Benakova, H. and Novotny, L. (2007) Relationship between serum bilirubin and markers of inflammation and oxidative stress. J. Gastroenterol. Hepatol. 22, A235.
146. Gullu, H., Erdogan, D., Tok, D., Topcu, S., Caliskan, M., Ulus, T. and Muderrisoglu, H. (2005) High serum bilirubin concentrations preserve coronary flow reserve and coronary microvascular functions. Arterioscler. Thromb. Vasc. Biol. 25, 2289-2294.
147. Verma, S. and Yeh, E.T. (2003) C-reactive protein and atherothrombosis-beyond a biomarker: an actual partaker of lesion formation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 285, R1253-R1256.
148. Bisht, K., Tampe, J., Shing, C., Bakrania, B., Winearls, J., Fraser, J., Wagner, K.H. and Bulmer, A.C. (2014) Endogenous tetrapyrroles influence leukocyte responses to lipopolysaccharide in human blood: pre-clinical evidence demonstrating the anti-inflammatory potential of biliverdin. J. Clin. Cell. Immunol. 5, 1000218.
149. Kundur, A.R., Bulmer, A.C. and Singh, I. (2014) Unconjugated bilirubin inhibits collagen induced platelet activation. Platelets 25, 45-50.
150. Sansanayudh, N., Anothaisintawee, T., Muntham, D., McEvoy, M., Attia, J. and AmmarinThakkinstian, J. (2014) Mean platelet volume and coronary artery disease: a systematic review and meta-analysis. Int. J. Cardiol. 175, 433-440.
151. Kim, Y.G., Suh, J.W., Yoon, C.H., Oh, I.Y., Cho, Y.S., Youn, T.J., Chae, I.H. and Choi, D.J. (2014) Platelet volume indices are associated with high residual platelet reactivity after antiplatelet therapy in patients undergoing percutaneous coronary intervention. J. Atheroscler. Thromb. 21, 445-453.
152. Cure, M.C., Cure, E., Kirbas, A., Cicek, A.C. and Yuce, S. (2013) The effects of Gilbert's syndrome on the mean platelet volume and other hematological parameters. Blood Coagul. Fibrinolysis 24, 484-488.
153. Tiker, F., Gurakan, B. and Tarcan, A. (2005) Relationship between serum bilirubin and coagulation test results in 1-month-old infants. Indian J. Pediatr. 72, 205-207.
154. Gutierrez, E., Flammer, A.J., Lerman, L.O., Elizaga, J., Lerman, A. and Fernandez-Aviles, F. (2013) Endothelial dysfunction over the course of coronary artery disease. Eur. Heart J. 34, 3175-3181.
155. Mazzone, G.L., Rigato, I., Ostrow, J.D., Bossi, F., Bortoluzzi, A., Sukowati, C.H., Tedesco, F. and Tiribelli, C. (2009) Bilirubin inhibits the TNF alpha-related induction of three endothelial adhesion molecules. Biochem. Biophys. Res. Commun. 386, 338-344.
156. Mazzone, G.L., Rigato, I., Ostrow, J.D. and Tiribelli, C. (2009) Bilirubin effect on endothelial adhesion molecules expression is mediated by the NF-kappaB signaling pathway. Biosci. Trends 3, 151-157.
157. Mazzone, G.L., Rigato, I. and Tiribelli, C. (2010) Unconjugated bilirubin modulates nitric oxide production via iNOS regulation. Biosci. Trends 4, 244-248.
158. Keshavan, P., Deem, T.L., Schwemberger, S.J., Babcock, G.F., Cook-Mills, J.M. and Zucker, S.D. (2005) Unconjugated bilirubin inhibits VCAM-1-mediated transendothelial leukocyte migration. J. Immunol. 174, 3709-3718.
159. Tapan, S., Dogru, T., Tasci, I., Ercin, C.N., Ozgurtas, T. and Erbil, M.K. (2009) Soluble CD40 ligand and soluble P-selectin levels in Gilbert's syndrome: a link to protection against atherosclerosis? Clin. Biochem. 42, 791-795.
160. Jirásková, A., Novotny, J., Novotny, L., Vodicka, P., Pardini, B., Naccarati, A., Schwertner, H.A., Hubacek, J.A., Puncocharova, L., Smerhovsky, Z. et al. (2012) Association of serum bilirubin and promoter variations in HMOX1 and UGT1A1 genes with sporadic colorectal cancer. Int. J. Cancer 131, 1549-1555.
161. Stoeckius, M., Erat, A., Fujikawa, T., Hiromura, M., Koulova, A., Otterbein, L., Bianchi, C., Tobiasch, E., Dagon, Y., Sellke, F.W. et al. (2012) Essential roles of raf/extracellular signal-regulated kinase/mitogen-activated protein kinase pathway, YY1, and Ca2+ influx in growth arrest of human vascular smooth muscle cells by bilirubin. J. Biol. Chem. 287, 15418-15426.
162. Ollinger, R., Bilban, M., Erat, A., Froio, A., McDaid, J., Tyagi, S., Csizmadia, E., Graca-Souza, A.V., Liloia, A., Soares, M.P. et al. (2005) Bilirubin-a natural inhibitor of vascular smooth muscle cell proliferation. Circulation 112, 1030-1038.
163. Ollinger, R., Yamashita, K., Bilban, M., Erat, A., Kogler, P., Thomas, M., Csizmadia, E., Usheva, A., Margreiter, R. and Bach, F.H. (2007) Bilirubin and biliverdin treatment of atherosclerotic diseases. Cell Cycle 6, 39-43.
164. Moraes, J.A., Barcellos-de-Souza, P., Rodrigues, G., Nascimento-Silva, V., Silva, S.V., Assreuy, J., Arruda, M.A. and Barja-Fidalgo, C. (2012) Heme modulates smooth muscle cell proliferation and migration via NADPH oxidase: a counter-regulatory role for heme oxygenase system. Atherosclerosis 224, 394-400.
165. Cesaratto, L., Calligaris, S.D., Vascotto, C., Deganuto, M., Bellarosa, C., Quadrifoglio, F., Ostrow, J.D., Tiribelli, C. and Tell, G. (2007) Bilirubin-induced cell toxicity involves PTEN activation through an APE1/Ref-1-dependent pathway. J. Mol. Med. 85, 1099-1112.
166. Dong, X., Yu, L.G., Sun, R., Cheng, Y.N., Cao, H., Yang, K.M., Dong, Y.N., Wu, Y. and Guo, X.L. (2013) Inhibition of PTEN expression and activity by angiotensin II induces proliferation and migration of vascular smooth muscle cells. J. Cell. Biochem. 114, 174-182.
167. Li, Y., Meng, S.Y., Meng, C.C., Yu, W.G. and Wang, R.T. (2013) Decreased serum bilirubin is associated with arterial stiffness in men. Nutr. Metab. Cardiovasc. Dis. 23, 375-381.
168. Zhang, Z.Y., Bian, L.Q., Jae, S.Y., Sung, J.D. and Choi, Y.H. (2013) Serum total bilirubin is inversely associated with brachial-ankle pulse wave velocity in men with hypertension. Heart Vessels 28, 453-460.
169. Erdogan, D., Gullu, H., Yildirim, E., Tok, D., Kirbas, I., Ciftci, O., Baycan, S.T. and Muderrisoglu, H. (2006) Low serum bilirubin levels are independently and inversely related to impaired flow-mediated vasodilation and increased carotid intima-media thickness in both men and women. Atherosclerosis 184, 431-437.
170. Caliskan, M., Erdogan, D., Gullu, H., Tok, D., Bilgi, M. and Muderrisoglu, H. (2007) Low serum bilirubin concentrations are associated with impaired aortic elastic properties, but not impaired left ventricular diastolic function. Int. J. Clin. Pract. 61, 218-224.
171. Erdogan, T., Cicek, Y., Kocaman, S.A., Canga, A., Cetin, M., Durakoglugil, E., Satiroglu, O., Temiz, A., Ergul, E., Sahin, I. et al. (2012) Increased serum bilirubin level is related to good collateral development in patients with chronic total coronary occlusion. Intern. Med. 51, 249-255.
172. Yoshino, S., Hamasaki, S., Ishida, S., Kataoka, T., Yoshikawa, A., Oketani, N., Saihara, K., Okui, H., Shinsato, T., Ichiki, H. et al. (2011) Relationship between bilirubin concentration, coronary endothelial function, and inflammatory stress in overweight patients. J. Atheroscler. Thromb. 18, 403-412.
173. Dekker, D., Dorresteijn, M.J., Pijnenburg, M., Heemskerk, S., Rasing-Hoogveld, A., Burger, D.M., Wagener, F.A. and Smits, P. (2011) The bilirubin-increasing drug atazanavir improves endothelial function in patients with type 2 diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 31, 458-463.
174. Brown, W.R., Moody, D.M., Challa, V.R., Thore, C.R. and Anstrom, J.A. (2002) Venous collagenosis and arteriolar tortuosity in leukoaraiosis. J. Neurol. Sci. 203-204, 159-163.
175. Ben-Assayag, E., Mijajlovic, M., Shenhar-Tsarfaty, S., Bova, I., Shopin, L. and Bornstein, N.M. (2012) Leukoaraiosis is a chronic atherosclerotic disease. Scientific World Journal 2012, 532141.
176. Park, K., Yasuda, N., Toyonaga, S., Yamada, S.M., Nakabayashi, H., Nakasato, M., Nakagomi, T., Tsubosaki, E. and Shimizu, K. (2007) Significant association between leukoaraiosis and metabolic syndrome in healthy subjects. Neurology 69, 974-978.
177. Park, B.J., Shim, J.Y., Lee, H.R., Kang, H.T., Lee, J.H. and Lee, Y.J. (2012) Association between serum total bilirubin level and leukoaraiosis in Korean adults. Clin. Biochem. 45, 289-292.
178. Kang, S.J., Park, B.J., Shim, J.Y., Lee, H.R., Hong, J.M. and Lee, Y.J. (2012) Mean platelet volume (MPV) is associated with leukoaraiosis in the apparently healthy elderly. Arch. Gerontol. Geriatr. 54, e118-e121.
179. Hsu, M., Muchova, L., Morioka, I., Wong, R.J., Schröder, H. and Stevenson, D.K. (2006) Tissue-specific effects of statins on the expression of heme oxygenase-1 in vivo. Biochem. Biophys. Res. Commun. 343, 738-744.
180. Szabó, M., Veres, Z., Bátai-Konczos, A., Kékesi, O., Kis, E., Szabó, K. and Jemnitz, K. (2014) Statins alter the hepatobiliary transport of unconjugated and conjugated bilirubin in sandwich-cultured rat hepatocytes. Toxicol. In Vitro 28, 1136-1143.
181. Hu, M. and Tomlinson, B. (2012) Effects of statin treatments and polymorphisms in UGT1A1 and SLCO1B1 on serum bilirubin levels in Chinese patients with hypercholesterolaemia. Atherosclerosis 223, 427-432.
182. Ong, K.L., Wu, B.J., Cheung, B.M., Barter, P.J. and Rye, KA. (2011) Association of lower total bilirubin level with statin usage: the United States National Health and Nutrition Examination Survey 1999-2008. Atherosclerosis 219, 728-733.
183. Vítek, L., Muchová, L. and Zák, A. (2011) Statin use and serum bilirubin levels. Atherosclerosis 219, 969.
184. de Sauvage Nolting, P.R., Kusters, D.M., Hutten, B.A. and Kastelein, J.J. (2011) Serum bilirubin levels in familial hypercholesterolemia: a new risk marker for cardiovascular disease? J. Lipid Res. 52, 1755-1759.
185. Zhang, D., Chando, T.J., Everett, D.W., Patten, C.J., Dehal, S.S. and Humphreys, W.G. (2005) In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab. Dispos. 33, 1729-1739.
186. Rotger, M., Taffe, P., Bleiber, G., Gunthard, H.F., Furrer, H., Vernazza, P., Drechsler, H., Bernasconi, E., Rickenbach, M. and Telenti, A.; Swiss HIV Cohort Study (2005) Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J. Infect. Dis. 192, 1381-1386.
187. Martinez, E., Gonzalez-Cordon, A., Ferrer, E., Domingo, P., Negredo, E., Gutierrez, F., Portilla, J., Curran, A., Podzamczer, D., Ribera, E. et al., (2015) Differential body composition effects of protease inhibitors recommended for initial treatment of hiv infection: a randomized clinical trial. Clin. Infect. Dis. 60, 811-820.
188. Morcos, P.A., Li, Y. and Jiang, S. (2008) Vivo-morpholinos: a non-peptide transporter delivers morpholinos into a wide array of mouse tissues. Biotechniques 45, 613-623.
189. Vera, T. and Stec, D.E. (2010) Moderate hyperbilirubinemia improves renal hemodynamics in ANG II-dependent hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol. 299, R1044-R1049.
190. Moulton, J.D. and Jiang, S. (2009) Gene knockdowns in adult animals: PPMOs and vivo-morpholinos. Molecules 25, 1304-1323.
191. Smit, R.A., Trompet, S., de Craen, A.J. and Jukema, J.W. (2014) Using genetic variation for establishing causality of cardiovascular risk factors: overcoming confounding and reverse causality. Neth. Heart J. 22, 186-189.
192. Ching, S., Ingram, D., Hahnel, R., Beilby, J. and Rossi, E. (2002) Serum levels of micronutrients, antioxidants and total antioxidant status predict risk of breast cancer in a case control study. J. Nutr. 132, 303-306.
193. Guillemette, C., De Vivo, I., Hankinson, S.E., Haiman, C.A., Spiegelman, D., Housman, D.E. and Hunter, D.J. (2001) Association of genetic polymorphisms in UGT1A1 with breast cancer and plasma hormone levels. Cancer Epidemiol. Biomarkers Prev. 10, 711-714.
194. Shatalova, E.G., Loginov, V.I., Braga, E.A., Kazubskaia, T.P., Sudomoina, M.A., Blanchard, R.L. and Favorova, O.O. (2006) [Association of polymorphisms in SULT1A1 and UGT1A1 Genes with breast cancer risk and phenotypes in Russian women]. Mol. Biol. (Mosk.) 40, 263-270.
195. Muraca, M. and Fevery, J. (1984) Influence of sex and sex steroids on bilirubin uridine diphosphate-glucuronosyltransferase activity of rat liver. Gastroenterology 87, 308-313.
196. Russo, J. and Russo, I.H. (2006) The role of estrogen in the initiation of breast cancer. J. Steroid Biochem. Mol. Biol. 102, 89-96.
197. ESHRE Capri Workshop Group (2006) Hormones and cardiovascular health in women. Hum. Reprod. Update 12, 483-497.
198. Yong, M., Schwartz, S.M., Atkinson, C., Makar, K.W., Thomas, S.S., Newton, K.M., Aiello Bowles, E.J., Holt, V.L., Leisenring, W.M. and Lampe, J.W. (2010) Associations between polymorphisms in glucuronidation and sulfation enzymes and mammographic breast density in premenopausal women in the United States. Cancer Epidemiol. Biomarkers Prev. 19, 537-546.
199. Ko, W.F., Helzlsouer, K.J. and Comstock, G.W. (1994) Serum albumin, bilirubin, and uric acid and the anatomic site-specific incidence of colon cancer. J. Natl. Cancer Inst. 86, 1874-1875.
200. Bajro, M.H., Josifovski, T., Panovski, M., Jankulovski, N., Nestorovska, A.K., Matevska, N., Petrusevska, N. and Dimovski, A.J. (2012) Promoter length polymorphism in UGT1A1 and the risk of sporadic colorectal cancer. Cancer Genet. 205, 163-167.
201. Lacko, M., Roelofs, H.M., Te Morsche, R.H., Voogd, A.C., Ophuis, M.B., Peters, W.H. and Manni, J.J. (2010) Genetic polymorphism in the conjugating enzyme UGT1A1 and the risk of head and neck cancer. Int. J. Cancer 127, 2815-2821.
202. Karakosta, M., Kalotychou, V., Kostakis, A., Pantelias, G., Rombos, I., Kouraklis, G. and Manola, K.N. (2014) UGT1A1*28 polymorphism in chronic lymphocytic leukemia: the first investigation of the polymorphism in disease susceptibility and its specific cytogenetic abnormalities. Acta Haematol. 132, 59-67.
203. Bonassi, S., El-Zein, R., Bolognesi, C. and Fenech, M. (2011) Micronuclei frequency in peripheral blood lymphocytes and cancer risk: evidence from human studies. Mutagenesis 26, 93-100.
204. Wallner, M., Blassnigg, S.M., Marisch, K., Pappenheim, M.T., Mullner, E., Molzer, C., Nersesyan, A., Marculescu, R., Doberer, D., Knasmuller, S. et al. (2012) Effects of unconjugated bilirubin on chromosomal damage in individuals with Gilbert's syndrome measured with the micronucleus cytome assay. Mutagenesis 27, 731-735.
205. Grant, D.J., Hall, I.J., Eastmond, D.A., Jones, I.M. and Bell, D.A. (2004) Bilirubin UDP-glucuronosyltransferase 1A1 (UGT1A1) gene promoter polymorphisms and HPRT, glycophorin A, and micronuclei mutant frequencies in human blood. Mutat. Res. 560, 1-10.
206. Wallner, M., Antl, N., Rittmannsberger, B., Schreidl, S., Najafi, K., Mullner, E., Molzer, C., Ferk, F., Knasmuller, S., Marculescu, R. et al. (2013) Anti-genotoxic potential of bilirubin in vivo: damage to DNA in hyperbilirubinemic human and animal models. Cancer Prev. Res. 6, 1056-1063.
207. Kim, P.M., Winn, L.M., Parman, T. and Wells, P.G. (1997) UDP-glucuronosyltransferase-mediated protection against in vitro DNA oxidation and micronucleus formation initiated by phenytoin and its embryotoxic metabolite 5-(p-hydroxyphenyl)-5-phenylhydantoin. J. Pharmacol. Exp. Ther. 280, 200-209.
208. Vienneau, D.S., DeBoni, U. and Wells, P.G. (1995) Potential genoprotective role for UDP-glucuronosyltransferases in chemical carcinogenesis: initiation of micronuclei by benzo(a)pyrene and benzo(e)pyrene in UDP-glucuronosyltransferase-deficient cultured rat skin fibroblasts. Cancer Res. 55, 1045-1051.
209. Gunn, C.H. (1938) Hereditary acholuric jaundice in a new mutant strain of rats. J. Hered. 29, 137-139.
210. Arimoto, S., Fukuoka, S., Itome, C., Nakano, H., Rai, H. and Hayatsu, H. (1993) Binding of polycyclic planar mutagens to chlorophyllin resulting in inhibition of the mutagenic activity. Mutat. Res. 287, 293-305.
211. Orlov, S., Goncharova, I. and Urbanova, M. (2014) Circular dichroism study of the interaction between mutagens and bilirubin bound to different binding sites of serum albumins. Spectrochim. Acta A Mol. Biol. Spectrosc. 126, 68-75.
212. Molzer, C., Huber, H., Steyrer, A., Ziesel, G.V., Wallner, M., Goncharova, I., Orlov, S., Urbanova, M., Ahlfors, C.E., Vitek, L. et al. (2013) Interaction between TNFone and tetrapyrroles may account for their anti-genotoxic effects-a novel mechanism for DNA-protection. J. Porphyrins Phthalocyanines 17, 1157-1166.
213. Keshavan, P., Schwemberger, S.J., Smith, D.L., Babcock, G.F. and Zucker, S.D. (2004) Unconjugated bilirubin induces apoptosis in colon cancer cells by triggering mitochondrial depolarization. Int. J. Cancer 112, 433-445.
214. Ollinger, R., Kogler, P., Troppmair, J., Hermann, M., Wurm, M., Drasche, A., Konigsrainer, I., Amberger, A., Weiss, H., Ofner, D. et al. (2007) Bilirubin inhibits tumor cell growth via activation of ERK. Cell Cycle 6, 3078-3085.
215. Molzer, C., Pfleger, B., Putz, E., Rossmann, A., Schwarz, U., Wallner, M., Bulmer, A.C. and Wagner, K.H. (2013) In vitro DNA-damaging effects of intestinal and related tetrapyrroles in human cancer cells. Exp. Cell Res. 319, 536-545.
216. Markesbery, W.R. and Lovell, M.A. (2007) Damage to lipids, proteins, DNA, and RNA in mild cognitive impairment. Arch. Neurol. 64, 954-956.
217. Kim, K.M., Kim, B.T., Park, S.B., Cho, D.Y., Je, S.H. and Kim, K.N. (2012) Serum total bilirubin concentration is inversely correlated with Framingham risk score in Koreans. Arch. Med. Res. 43, 288-293.
218. Butterfield, D.A., Drake, J., Pocernich, C. and Castegna, A. (2001) Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol. Med. 7, 548-554.
219. Butterfield, D.A., Swomley, A.M. and Sultana, R. (2013) Amyloid beta-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression. Antioxid. Redox Signal. 19, 823-835.
220. Kimpara, T., Takeda, A., Yamaguchi, T., Arai, H., Okita, N., Takase, S., Sasaki, H. and Itoyama, Y. (2000) Increased bilirubins and their derivatives in cerebrospinal fluid in Alzheimer's disease. Neurobiol. Aging 21, 551-554.
221. Barone, E., Di Domenico, F., Mancuso, C. and Butterfield, D.A. (2014) The Janus face of the heme oxygenase/biliverdin reductase system in Alzheimer disease: it's time for reconciliation. Neurobiol. Dis. 62, 144-159.
222. Schipper, H.M. (2004) Heme oxygenase-1: transducer of pathological brain iron sequestration under oxidative stress. Ann. N.Y. Acad. Sci. 1012, 84-93.
223. Scigliano, G., Girotti, F., Soliveri, P., Musicco, M., Radice, D. and Caraceni, T. (1997) Increased plasma bilirubin in Parkinson patients on L-dopa: evidence against the free radical hypothesis? Ital. J. Neurol. Sci. 18, 69-72.
224. Li, R.Y., Cao, Z.G., Zhang, J.R., Li, Y. and Wang, R.T. (2014) Decreased serum bilirubin is associated with silent cerebral infarction. Arterioscler. Thromb. Vasc. Biol. 34, 946-951.
225. Peng, F., Deng, X., Yu, Y., Chen, X., Shen, L., Zhong, X., Qiu, W., Jiang, Y., Zhang, J. and Hu, X. (2011) Serum bilirubin concentrations and multiple sclerosis. J. Clin. Neurosci. 18, 1355-1359.
226. Ilzecka, J. and Stelmasiak, Z. (2003) Serum bilirubin concentration in patients with amyotrophic lateral sclerosis. Clin. Neurol. Neurosurg. 105, 237-240.
227. Muller, N., Schiller, P. and Ackenheil, M. (1991) Coincidence of schizophrenia and hyperbilirubinemia. Pharmacopsychiatr 24, 225-228.
228. Miyaoka, T., Seno, H., Itoga, M., Iijima, M., Inagaki, T. and Horiguchi, J. (2000) Schizophrenia-associated idiopathic unconjugated hyperbilirubinemia (Gilbert's syndrome). J. Clin. Psychiatry 61, 868-871.
229. Yao, J.K., Reddy, R., McElhinny, L.G. and van Kammen, D.P. (1998) Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr. Res. 32, 1-8.
230. Pae, C.U., Paik, I.H., Lee, C., Lee, S.J., Kim, J.J. and Lee, C.U. (2004) Decreased plasma antioxidants in schizophrenia. Neuropsychobiology 50, 54-56.
231. Vitek, L., Novotna, M., Lenicek, M., Novotny, L., Eberova, J., Petrasek, J. and Jirsa, M. (2010) Serum bilirubin levels and UGT1A1 promoter variations in patients with schizophrenia. Psychiatry. Res. 178, 449-450.
232. Oren, D.A., Desan, P.H., Boutros, N., Anand, A. and Charney, D.S. (2002) Effects of light on low nocturnal bilirubin in winter depression: a preliminary report. Biol. Psychiatry 51, 422-425.
233. Oren, D.A. and Terman, M. (1998) Tweaking the human circadian clock with light. Science 279, 333-334.
234. Seta, F., Bellner, L., Rezzani, R., Regan, R.F., Dunn, M.W., Abraham, N.G., Gronert, K. and Laniado-Schwartzman, M. (2006) Heme oxygenase-2 is a critical determinant for execution of an acute inflammatory and reparative response. Am. J. Pathol. 169, 1612-1623.
235. Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89-95.
236. Knasmuller, S., Nersesyan, A., Misik, M., Gerner, C., Mikulits, W., Ehrlich, V., Hoelzl, C., Szakmary, A. and Wagner, K.H. (2008) Use of conventional and-omics based methods for health claims of dietary antioxidants: a critical overview. Br. J. Nutr. 9 (E Suppl. 1), ES3-ES52.
237. Weber, M. and Hamm, C. (2006) Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart 92, 843-849.
238. Gillett, M.J. (2009) International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes: Diabetes Care 2009;32(7):1327-1334. Clin. Biochem. Rev. 30, 197-200.
239. Keller, T., Zeller, T., Peetz, D., Tzikas, S., Roth, A., Czyz, E., Bickel, C., Baldus, S., Warnholtz, A., Frohlich, M. et al. (2009) Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N. Engl. J. Med. 361, 868-877.
240. Ridker, P.M. (2003) Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107, 363-369.
241. European Food Safety Authority (EFSA) Panel on Dietetic Products (2011) Guidance on the scientific requirements for health claims related to antioxidants, oxidative damage and cardiovascular health. EFSA J. 9, 2474.
242. Sistrom, C.L. and Garvan, C.W. (2004) Proportions, odds, and risk. Radiology 230, 12-19.
243. Kundur, A.R., Bulmer, A.C. and Singh, I. (2015) Bilirubin, platelet activation and heart disease: a missing link to cardiovascular protection in Gilbert's syndrome? Atherosclerosis 239, 73-84.
244. Dore, S., Takahashi, M., Ferris, C.D., Zakhary, R., Hester, L.D., Guastella, D. and Snyder, S.H. (1999) Bilirubin, formed by activation of heme oxygenase-2, protects neurons against oxidative stress injury. Proc. Natl. Acad. Sci. U.S.A. 96, 2445-2450.
245. Baranano, D.E., Rao, M., Ferris, C.D. and Snyder, S.H. (2002) Biliverdin reductase: a major physiologic cytoprotectant. Proc. Natl. Acad. Sci. U.S.A. 99, 16093-16098.
246. Sedlak, T.W. and Snyder, S.H. (2004) Bilirubin benefits: cellular protection by a biliverdin reductase antioxidant cycle. Pediatrics 113, 1776-1782.